Cargando…
Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation
Clinical application of siRNA-based therapeutics outside of the liver has been hindered by the inefficient delivery of siRNA effector molecules into extra-hepatic organs and cells of interest. To understand the parameters that enable RNAi activity in vivo, it is necessary to develop a systematic app...
Autores principales: | Ng, Bruce, Cash-Mason, Tanesha, Wang, Yi, Seitzer, Jessica, Burchard, Julja, Brown, Duncan, Dudkin, Vadim, Davide, Joseph, Jadhav, Vasant, Sepp-Lorenzino, Laura, Cejas, Pedro J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426712/ https://www.ncbi.nlm.nih.gov/pubmed/30901578 http://dx.doi.org/10.1016/j.omtn.2019.02.013 |
Ejemplares similares
-
Centyrin ligands for extrahepatic delivery of siRNA
por: Klein, Donna, et al.
Publicado: (2021) -
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth
por: Khan, Tayeba, et al.
Publicado: (2016) -
Intratracheal administration of siRNA targeting FAS reduces ischemia-reperfusion-induced lung injury
por: Del Sorbo, L, et al.
Publicado: (2012) -
siRNA off-target effects in genome-wide screens identify signaling pathway members
por: Buehler, Eugen, et al.
Publicado: (2012) -
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
por: Schwarz, Dianne S, et al.
Publicado: (2006)